Inozyme Pharma, Inc.

Inozyme Pharma engages in the research and development of novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Its lead product candidate is INZ-701, which is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

– Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway –

Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Sanjay S. Subramanian, M.S., MBA, as chief financial officer (CFO), effective as of the later of (i) March 21, 2022 and (ii) the date immediately following the date of the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and Soojin Kim, Ph.D., as senior vice president and chief technical operations officer (CTOO). Dr. Kim succeeds Inozyme senior vice president and CTOO, Steven Jungles, who has retired from the Company.

Inozyme Pharma Strengthens Management Team with Two Executive Appointments

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8th at 11:10 AM ET.

Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference

The shares of Inozyme Pharma Inc (NASDAQ: INZY) have received a $23 price target from Needham. These are the details.

Inozyme Pharma (INZY) Stock: $23 Price Target From Needham

- Preliminary biomarker and safety data expected in the first half of 2022 - - Preliminary biomarker and safety data expected in the first half of 2022 -

Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

The average of price targets set by Wall Street analysts indicates a potential upside of 256.5% in Inozyme Pharma, Inc. (INZY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Inozyme Pharma, Inc. (INZY) Could Rally 257%: Here's is How to Trade

- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets -

Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting

The stock price of Inozyme Pharma Inc (NASDAQ: INZY) increased by over 15% during intraday trading today. This is why it happened.

INZY Stock: Why It Increased Today

BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, at 1:20 p.m. ET.

Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency –

Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in a panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug. 11. Members of the Inozyme management team will also host investor meetings during the conference.

Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference

INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that Gayle Gironda has been appointed as senior vice president of human resources. Ms. Gironda is a human resources leader with more than 20 years of experience in organizational design, talent recruitment, performance culture, planning and leadership development.

Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources

- Clinical trial initiation expected in mid-2021 – - Preliminary safety and biomarker data expected by the end of 2021 -

Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency

– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 –

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights

Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in an animal model of PXE Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in an animal model of PXE

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

- Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse model -

Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the potential treatment for ABCC6 Deficiency/Pseudoxanthoma elasticum (PXE) will be presented at the following upcoming medical conferences:

Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences

- Study results underscore high and shifting disease impacts across age groups, reflecting evolution of disease symptomology - - Study results underscore high and shifting disease impacts across age groups, reflecting evolution of disease symptomology -

Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced that data from the burden of illness in infantile onset ABCC6 and ENPP1 deficiency study will be presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting taking place April 13-16, 2021.

Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting

- Appoints veteran leaders with deep scientific and clinical expertise in vascular calcification, renal disease, and diseases with neointimal proliferation - - Appoints veteran leaders with deep scientific and clinical expertise in vascular calcification, renal disease, and diseases with neointimal proliferation -

Inozyme Pharma Expands its Scientific Advisory Board

– Received Orphan Drug Designation by the U.S. Food and Drug Administration for INZ-701 for treatment of ABCC6 deficiency –

Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights

Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis  Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis

The Balancing Act® on Lifetime to Feature ENPP1 Deficiency

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today announced the appointment of Deborah Wenkert, M.D. as senior vice president and chief medical officer, effective February 2, 2021.

Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer

– U.S. Food and Drug Administration cleared Investigational New Drug Application –

News for Inozyme Pharma, Inc. Stock (INZY)